Spike in South Korea flu shot deaths fuels vaccine doubts

Spike in South Korea flu shot deaths fuels vaccine doubts. At least 13 South Koreans have died after receiving flu shots in recent days, according to official and local media reports, fuelling doubts about vaccine safety even as authorities preclude a connection and as global efforts to discover a vaccine against COVID-19 intensify.

Health authorities said on Wednesday there were no designs to suspend the program to vaccinate approximately 19 million people for free after a preliminary investigation into six deaths found no direct connection with the drug they had received.

“The number of deaths has increased, but our team sees low possibility that the deaths resulted from the shots,” Jeong Eun-kyeong, director of the Korea Disease Control and Prevention Agency (KDCA), told parliament.

South Korea ordered 20 percent more flu vaccines this year to stay away from what it calls a “twindemic” of people with flu developing potential COVID-19 complications, and overburdening hospitals throughout the winter.

“I understand and regret that people are concerned about the vaccine,” Health Minister Park Neung-hoo said on Thursday, while confirming the free program would continue.

“We’re investigating the causes but will again thoroughly analyze the entire process wherein various government agencies are involved, from production to distribution,” he added.

The deaths, including a 17-year-old boy and a man in his 70s, took place just seven days after the resumption of the vaccination program for teenagers and senior citizens on October 13.

No toxic substances had been found in the vaccines and at least five of the six people investigated had underlying conditions, officials said.


The inoculation program was suspended for three weeks after it was discovered that some 5,000,000 portions, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility. South Korea’s vaccines come from a variety of sources.

Manufacturers include local drug producers GC Pharma, SK Bioscience and Il-Yang Pharmaceutical Co, along with France’s Sanofi and Britain’s GlaxoSmithKline. Distributors include LG Chem and Boryung Biopharma, a unit of Boryung Pharm.

GC Pharma, LG Chem, SK Bioscience and Boryung declined to comment. Il-Yang Pharmaceutical, Sanofi and GSK could not immediately be reached for comment.

South Korea has extended its seasonal vaccine program this year to dodge any potential complications as a result of COVID-19 complications.

The country has reported more than 25,500 cases of the coronavirus, holding the disease under wraps through a robust contact-tracing and testing regime and physical-distancing measures, as the world rushes to develop an effective vaccine against the disease.

Officials said 8.3 million people have been inoculated with the free flu vaccine since it resumed on October 13, with about 350 cases of adverse reactions reported.

It is also offering a paid vaccine program which, combined with the free program, means to ensure about 30 million of the country’s 52-million population are inoculated. Under the paid program, the buyer can select the vaccine provider from a larger pool of manufacturers.

Kim Myung-suk, 65, who is eligible for a free vaccine, was among a growing number of people opting to pay. “Though just a couple of people died so far, the number is growing and that makes me uneasy,” she told Reuters news agency in Seoul. “So I’m getting a shot somewhere else and will pay for it.”

The highest number of deaths linked to the seasonal flu vaccination was six of every 2005, according to the Yonhap news agency. Officials have said it is difficult to make comparisons to previous years because of the greater numbers of people taking the vaccine this year.

Read More Article…

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

World News Today will use the information you provide on this form to be in touch with you and to provide updates and marketing.